Johnson & Johnson Development Corporation

Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US. The paradigm of screening, detection, and early intervention that has been deployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer. Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company's therapeutics are designed to significantly reduce the mortality and morbidity associated with these infections, as well as the related healthcare costs. Osteal Therapeutics offers solutions for orthopedic infections, including those affecting infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for musculoskeletal diseases, enhancing patient outcomes and addressing a critical need in the field of infection therapeutics.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company's therapeutics are designed to significantly reduce the mortality and morbidity associated with these infections, as well as the related healthcare costs. Osteal Therapeutics offers solutions for orthopedic infections, including those affecting infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for musculoskeletal diseases, enhancing patient outcomes and addressing a critical need in the field of infection therapeutics.

Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US. The paradigm of screening, detection, and early intervention that has been deployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer. Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company focused on developing innovative drug and device combination products aimed at treating musculoskeletal infections. The company's therapeutics are designed to significantly reduce the mortality and morbidity associated with these infections, as well as the related healthcare costs. Osteal Therapeutics offers solutions for orthopedic infections, including those affecting infected joint prostheses, providing fast and reliable treatment options. This enables orthopedic surgeons to deliver effective care for musculoskeletal diseases, enhancing patient outcomes and addressing a critical need in the field of infection therapeutics.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50, and DAC, a diagnostic aid that enhances the resolution of cancer testing for patients with clinical suspicion of cancer. The company’s signature product is a multi-cancer early detection blood test that utilizes high-intensity sequencing to measure circulating nucleic acids, allowing for the identification of various cancer types at early stages. GRAIL is also working on developing minimal residual disease tests and other post-diagnostic assessments to further enhance cancer detection and treatment.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Willow, founded in 2014 and based in Mountain View, California, is a company that specializes in the development and manufacturing of wearable breast pumps and related breastfeeding products. The company offers a range of items including in-bra breast pumps, milk bags, replacement parts, pumping bras, and accessories like flanges and chargers. Willow's breast pumps are designed to be mobile and hands-free, allowing mothers to pump discreetly and conveniently. The devices are cordless, spill-proof, and equipped with a mobile application that tracks milk output, facilitating a hassle-free pumping experience for mothers on the go.

Padlock Therapeutics is a biotechnology company focused on developing innovative medicines that target protein-arginine deiminases (PADs), enzymes implicated in the generation of autoantigens and the inflammatory processes associated with autoimmune diseases. Founded by scientists from The Scripps Research Institute and members of the Atlas Venture Life Sciences Team, Padlock aims to explore the biological and therapeutic potential of protein deimination by PADs. The company operates as a seed-stage entity based in Cambridge, Massachusetts, and is backed by notable investors, including Atlas Venture, Johnson & Johnson, and MS Ventures.

La Lumière is a skincare device company focused on making advanced skincare technologies accessible for home use. It has created a proprietary line of light therapy devices marketed under the brand illuMask, specifically designed to address issues such as acne and signs of aging. The company utilizes a combination of red and infrared light-emitting diode (LED) technology in its wearable masks, providing users with effective treatment options. La Lumière's team comprises experts in product development, manufacturing, and health and beauty marketing, along with guidance from notable dermatologists and plastic surgeons, ensuring a well-rounded approach to skincare innovation.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. Inivata's innovative approach utilizes TAm-Seq technology to detect and analyze genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples, known as liquid biopsies. This method revolutionizes cancer detection and monitoring by providing a less invasive alternative to traditional biopsies. The company's focus is on enabling clinicians to make more informed treatment decisions by monitoring response to therapies and detecting potential relapses in cancer patients. Inivata has also formed a strategic collaboration with NeoGenomics, Inc.

Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

Aduro Biotech, a clinical-stage biopharmaceutical company founded in 2000 and based in Berkeley, California, specializes in the discovery, development, and commercialization of therapies aimed at leveraging the body's natural immune system to treat challenging diseases. The company is currently advancing several candidates, including ADU-S100, which is undergoing multiple clinical trials for various forms of cancer, including advanced solid tumors and melanoma. Additionally, Aduro is developing BION-1301, a monoclonal antibody for IgA nephropathy, and exploring the potential of CD27, a co-stimulatory receptor involved in immune response, in preclinical studies. Collaborations with prominent pharmaceutical companies and research institutions further enhance Aduro's capabilities in immunotherapy research and development.

Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).

Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for obstructive sleep apnea (OSA). The company has created the Inspire system, a neurostimulation technology designed to provide safe and effective treatment for moderate to severe OSA. This system employs a proprietary Upper Airway Stimulation (UAS) therapy that utilizes established technologies from cardiac pacing and neurostimulation. Additionally, Inspire is developing a novel closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to keep the airway open. Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire primarily generates its revenue in the United States, with a growing presence in Europe.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, established in 2011. It specializes in developing innovative therapeutics for skin disorders, particularly atopic dermatitis and acne. Unlike many companies that primarily reformulate existing treatments with limited advancements, Thesan is dedicated to discovering and developing New Chemical Entities aimed at significantly improving patient outcomes. Through its commitment to innovation, Thesan seeks to address the gaps in dermatological care and provide healthcare providers with effective treatment options for their patients.

PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.

TopiVert Ltd. is a clinical-stage biotechnology company based in London, United Kingdom, focused on developing narrow spectrum kinase inhibitors as locally-acting treatments for chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, the company is advancing its lead program, TOP1288, which is undergoing a Phase IIa proof of concept study for ulcerative colitis. Additionally, TopiVert is preparing to initiate a Phase I/II study for its second program, TOP1630, aimed at addressing dry eye syndrome. The company's innovative approach enables the delivery of medications at pharmacologically relevant concentrations directly to the targeted areas, potentially leading to improved treatment outcomes for patients.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.

Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on developing peptide-based product candidates to meet unmet medical needs in hematology and gastroenterology. The company is advancing several key products, including PTG-300, an injectable hepcidin mimetic in Phase II clinical trials for treating beta-thalassemia-related anemia, and PTG-200, an antagonist peptide that has completed Phase I trials aimed at moderate-to-severe Crohn's disease. Additionally, PN-943, an oral integrin antagonist, is in Phase I trials for inflammatory bowel disease. Protagonist also explores both oral and injectable peptide candidates for various gastrointestinal conditions. The company has established a collaboration with Janssen Biotech for the development and commercialization of PTG-200. Founded in 2006, Protagonist Therapeutics is headquartered in Newark, California.

ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.

Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for hemophilia and other rare bleeding disorders. The company specializes in subcutaneous (SQ) coagulation factors designed to enhance blood clotting and improve patient outcomes compared to traditional intravenous (IV) therapies. Its product portfolio includes Marzeptacog alfa (activated), an engineered Factor VIIa that has completed Phase II development for hemophilia A or B patients with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has undergone Phase IIb clinical trials for hemophilia B. Additionally, Catalyst is developing CB 2679d-GT, a Factor IX gene therapy for hemophilia B, and CB 2782-PEG, a long-acting anti-C3 protease for dry age-related macular degeneration (AMD). The company has strategic collaborations with Mosaic Biosciences, Inc. for anti-complement factor 3 products and with Biogen International GmbH for the commercialization of pegylated CB 2782 targeting geographic atrophy associated with dry AMD. Established in 2002, Catalyst Biosciences is headquartered in South San Francisco, California.

Nevro is a global medical device company dedicated to enhancing the quality of life for patients suffering from chronic pain. The company's primary product is the HFX spinal cord stimulation (SCS) platform, which features the Senza SCS system. This innovative neuromodulation system delivers Nevro's proprietary HF10 therapy, designed to provide effective pain relief through electrical impulses. The Senza system, which is implanted by physicians, includes essential components such as leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro primarily generates its revenue from the United States market, focusing on evidence-based solutions for chronic pain management.

CoStim Pharmaceuticals Inc. operates as a biotechnology company. It develops antibody agents for treatment of cancer. The company was incorporated in 2011 and is based in Boston, Massachusetts.

OptiScan Biomedical Corporation specializes in developing advanced glucose monitoring systems for use in intensive care units. The company is known for its OptiScanner 5000, an automated bedside platform that provides precise plasma-based glucose measurements using spectroscopy technology, eliminating the need for calibration. This system enables healthcare providers to monitor and respond to changes in glucose levels for critically ill patients effectively. Founded in 1994 and headquartered in Hayward, California, OptiScan Biomedical faced financial challenges, filing for Chapter 11 bankruptcy in June 2020 and subsequently converting to Chapter 7 bankruptcy in November 2020.

Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for hemophilia and other rare bleeding disorders. The company specializes in subcutaneous (SQ) coagulation factors designed to enhance blood clotting and improve patient outcomes compared to traditional intravenous (IV) therapies. Its product portfolio includes Marzeptacog alfa (activated), an engineered Factor VIIa that has completed Phase II development for hemophilia A or B patients with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has undergone Phase IIb clinical trials for hemophilia B. Additionally, Catalyst is developing CB 2679d-GT, a Factor IX gene therapy for hemophilia B, and CB 2782-PEG, a long-acting anti-C3 protease for dry age-related macular degeneration (AMD). The company has strategic collaborations with Mosaic Biosciences, Inc. for anti-complement factor 3 products and with Biogen International GmbH for the commercialization of pegylated CB 2782 targeting geographic atrophy associated with dry AMD. Established in 2002, Catalyst Biosciences is headquartered in South San Francisco, California.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

Celladon Corporation is a biotechnology company focused on developing molecular therapies for the treatment of heart failure. Founded in 2000 and headquartered in La Jolla, California, the company is known for its product candidates that address key enzyme deficiencies associated with advanced heart failure. One of its primary products, SERCA2a, is an enzyme that plays a crucial role in calcium cycling and contractility in heart muscle cells. Additionally, Celladon is developing MYDICAR, an enzyme replacement therapy aimed at improving heart function in patients suffering from heart failure.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

PowerVision, Inc. is a company that specializes in the development of innovative intraocular lenses aimed at restoring vision for individuals suffering from presbyopia and cataracts. Founded in 2002 and based in Belmont, California, PowerVision has created the FluidVision accommodating intraocular lens, which utilizes a unique fluid-controlled mechanism to mimic the natural function of a healthy eye. This technology allows users to dynamically adjust their focus for clear vision at all distances, potentially liberating millions from the need for glasses or other vision correction methods. The FluidVision lens is designed to meet the clinical and lifestyle needs of patients, offering a significant advancement in vision correction surgery. PowerVision's approach addresses the visual impairments faced by over 20 million people in the United States with cataracts and more than 90 million individuals affected by presbyopia, particularly those in their 40s and 50s.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.

NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.

Nevro is a global medical device company dedicated to enhancing the quality of life for patients suffering from chronic pain. The company's primary product is the HFX spinal cord stimulation (SCS) platform, which features the Senza SCS system. This innovative neuromodulation system delivers Nevro's proprietary HF10 therapy, designed to provide effective pain relief through electrical impulses. The Senza system, which is implanted by physicians, includes essential components such as leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro primarily generates its revenue from the United States market, focusing on evidence-based solutions for chronic pain management.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.

Zeo was a manufacturer of a sleep monitor in the form of a headband, that contained an EEG unit monitoring the user's brain waves. The sleep monitor was able to detect and record sleep stages, and awake at the optimal time, in light sleep. Using analytics, users were provided with recommendations based on each individual's sleeping patterns. Zeo has stopped operating in [December 2012](http://techcrunch.com/2013/05/22/sleep-tracking-startup-zeo-says-goodnight/), and Q2 2013, it quietly shut down. According to founder Dave Dickinson, problems included the business model, with a "suboptimal profit margin", invasiveness of the headband device for some user, and friction caused by the user having to log into the website to enter additional data. Moreover, the [sleep data was not necessarily suitable for a small mobile screen](http://mobihealthnews.com/22410/can-personal-health-data-motivate-behavioral-change-it-depends/).

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.

INTIO Inc. is a company specializing in the development of software tools aimed at enhancing interventional oncology practices. Founded in 2005 and based in Colorado, INTIO creates innovative software solutions that assist in planning, monitoring, and analyzing image-guided treatments for both malignant and benign solid tumors. Key products include ClearStart SVM, which offers segmentation and volumetric measurement from CT scans, and TipTRAC, which provides real-time feedback to physicians regarding probe placement in relation to tumors. Additionally, the SyncVIEW module allows oncologists to visualize segmented lesions and post-treatment results, while ClearView offers real-time visualization during thermal ablation procedures. INTIO's focus encompasses a range of interventional oncology therapies, including surgery, ablation, and palliative care, facilitating more accurate and effective cancer treatment. The company was previously known as Abla-Tx Inc. before rebranding in 2009.

Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.

Breathe Technologies, Inc. is a medical technology company based in Irvine, California, that specializes in developing and manufacturing innovative respiratory therapies for treating respiratory insufficiency diseases. Founded in 2005, the company focuses on creating non-invasive open ventilation systems aimed at helping patients with conditions such as interstitial lung diseases, neuromuscular disorders, and those undergoing lung transplants. Their lightweight, volume-control mechanical ventilators are designed to enhance patient mobility and are suitable for use in various healthcare settings, including general medical units, intensive care, and pulmonary rehabilitation. As a subsidiary of Hill-Rom, Breathe Technologies is committed to providing reliable and accessible solutions that optimize breathing and improve the quality of life for patients both in hospital and home environments.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Spinal Modulation, Inc., based in Menlo Park, California, specializes in the research and development of medical devices aimed at treating chronic pain. With a significant portion of the adult population affected by severe chronic pain and limited treatment options available, the company addresses this critical healthcare challenge through its Axium Neurostimulator System. This next-generation intraspinal neuromodulation therapy specifically targets the dorsal root ganglion (DRG) to deliver electrical pulses that disrupt pain signals before they reach the brain. The system has demonstrated effectiveness in managing chronic intractable leg pain and other complex pain areas, such as the back and foot, providing a tailored approach for pain relief. By allowing adjustments to focus on either broad or specific pain areas, Spinal Modulation's technology aims to enhance patient comfort and reduce the adverse effects commonly associated with traditional spinal cord stimulators.

Celladon Corporation is a biotechnology company focused on developing molecular therapies for the treatment of heart failure. Founded in 2000 and headquartered in La Jolla, California, the company is known for its product candidates that address key enzyme deficiencies associated with advanced heart failure. One of its primary products, SERCA2a, is an enzyme that plays a crucial role in calcium cycling and contractility in heart muscle cells. Additionally, Celladon is developing MYDICAR, an enzyme replacement therapy aimed at improving heart function in patients suffering from heart failure.

Sleep Solutions (SSI) is a privately held diagnostic service provider for home testing and evaluation of sleep-disordered breathing, which includes the diagnosis of Obstructive Sleep Apnea (OSA). Sleep Solutions® offers physicians and their patients a fast, cost-effective, accurate and comfortable alternative to in-laboratory sleep studies. Utilizing proprietary sound analysis technology, their NovaSom® QSG® home-diagnostic system is delivered directly to the patient.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

NovoCure Limited is an oncology company focused on the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) therapy, specifically through its flagship product, Optune. This innovative treatment targets solid tumors, including glioblastoma, by utilizing electric fields to disrupt cancer cell division, thereby slowing or reversing tumor progression. In addition to Optune, the company is advancing a pipeline of products, including those in Phase 2 and Phase 3 clinical trials for various cancers such as brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. NovoCure markets its devices in the European Union, Japan, and other international markets, and has established collaborations to enhance its research and development efforts. Founded in 2000 and headquartered in Saint Helier, Jersey, NovoCure aims to provide effective treatment options for patients battling cancer through its innovative technology.

NeoTract, Inc. is a medical device company specializing in minimally invasive solutions for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, it develops the UroLift system, which is specifically designed for men suffering from enlarged prostate. This system addresses symptoms effectively while preserving normal sexual function. NeoTract serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, the company is committed to providing innovative clinical devices that improve patient outcomes in urology and gynecology.

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the Nasdaq OMX Copenhagen A/S. The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company, Janssen Pharmaceutica and GlaxoSmithKline (GSK), and a license collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies. The company has approximately 220 employees with activities in Ballerup and Gothenburg.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in solutions for cerebral ischemia. The company develops innovative devices aimed at controlling blood flow, specifically the NeuroFlo and FloControl systems. These devices are designed to redirect blood flow to the brain, thereby helping to reduce the risk of stroke and heart attack in patients experiencing conditions such as vasospasm and heart blockage. Through its research and development efforts, CoAxia focuses on improving treatment outcomes for individuals suffering from these serious medical conditions.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

GetWellNetwork, Inc. is a company that specializes in developing interactive software solutions aimed at enhancing patient engagement in healthcare settings. Founded in 1999 and based in Bethesda, Maryland, the company provides a range of products including a patient care model that combines technology and processes to activate patient involvement in their care. Key offerings include digital patient check-in, integrated entertainment and educational resources for patients, and personalized care solutions that deliver real-time information to healthcare providers. The company's platform also features a patient engagement index to assess individual patient capacities and customizable digital rounding tools for healthcare teams. By utilizing bedside technology, GetWellNetwork aims to create a more patient-centered care experience, offering educational content tailored to specific health conditions while also providing entertainment options. The company serves a diverse clientele, including healthcare providers, pediatric hospitals, and government organizations, with an overarching goal of improving patient outcomes and overall satisfaction in the care continuum.

GI Dynamics, Inc., a medical device company, develops therapies for the treatment of type 2 diabetes and related metabolic diseases in the United States. Its products also include EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. The company was founded in 2003 and is based in Lexington, Massachusetts.

ImaCor develops advanced medical devices focused on cardiac monitoring and management. The company's primary offerings include the ClariTEE probe and the Zura imaging system, which are designed for hemodynamic management, echocardiography, and transesophageal echocardiography. These devices enable direct visualization of cardiac performance over time, allowing clinicians to optimize patient outcomes and healthcare resource utilization. By providing efficient monitoring solutions, ImaCor aims to enhance clinical decision-making and improve the overall effectiveness of cardiac care.

7TM Pharma is a biotech company established in 2000 and located in Lyngby, Hovedstaden. The company specializes in discovering and developing therapeutic drugs aimed at addressing significant unmet medical needs in various conditions, particularly diabetes, obesity, gastrointestinal, metabolic, asthma, and vascular diseases. Among its key offerings are TM38837, a small molecule CB1 receptor antagonist, and TM30339, a selective NPY Y4 agonist designed to treat gastrointestinal disorders and short bowel syndrome. Additionally, the company has developed a CRTH2 antagonist, an oral medication targeting inflammatory and respiratory diseases. Through its innovative approaches, 7TM Pharma strives to provide effective treatments for patients suffering from these conditions.

Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for hemophilia and other rare bleeding disorders. The company specializes in subcutaneous (SQ) coagulation factors designed to enhance blood clotting and improve patient outcomes compared to traditional intravenous (IV) therapies. Its product portfolio includes Marzeptacog alfa (activated), an engineered Factor VIIa that has completed Phase II development for hemophilia A or B patients with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has undergone Phase IIb clinical trials for hemophilia B. Additionally, Catalyst is developing CB 2679d-GT, a Factor IX gene therapy for hemophilia B, and CB 2782-PEG, a long-acting anti-C3 protease for dry age-related macular degeneration (AMD). The company has strategic collaborations with Mosaic Biosciences, Inc. for anti-complement factor 3 products and with Biogen International GmbH for the commercialization of pegylated CB 2782 targeting geographic atrophy associated with dry AMD. Established in 2002, Catalyst Biosciences is headquartered in South San Francisco, California.

Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for patients with central nervous system diseases. The company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Currently, BrainsGate is focused on treating acute ischemic stroke through its innovative ischemic stroke system, which involves a miniature electrode implanted in the roof of the mouth during a minimally invasive procedure. This method is performed under local anesthesia and is comparable to standard dental treatments. The company has conducted several clinical trials, including a pivotal trial with 300 patients that validated the safety and efficacy of its treatment. BrainsGate is also engaged in a multi-national, randomized study known as ImpACT-24b, aimed at further assessing the effectiveness of its approach within a critical 24-hour window following a stroke.

Neuron Systems is a mass-based drug developer for the treatment of retinal diseases.

CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Arbor Surgical Technologies, Inc. located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

Tengion is a clinical-stage biotechnology company focused on regenerative medicine, specializing in the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Tengion Neo-Bladder Augment, aimed at treating children with neurogenic bladder due to spina bifida and adults with neurogenic bladder resulting from spinal cord injury. Tengion's innovative approach seeks to eliminate the need for donor organs or anti-rejection medications by creating living cellular products that can regenerate or replace damaged tissues and organs. Additionally, the company has an investigational new drug application for its Neo-Urinary Conduit and plans to initiate a Phase 1 clinical trial for bladder cancer patients requiring bladder removal. Through its proprietary technology, Tengion aims to enhance patient outcomes by offering alternative solutions for organ and tissue repair.